Efficacy and safety of lobeglitazone added to metformin and sitagliptin combination therapy in patients with type 2 diabetes: A 52-week, multicentre, randomized, placebo-controlled, phase III clinical trial.
Eun-Gyoung Hong, Kyung-Wan Min, SungWan Chun, Choon Hee Chung, Seungjoon Oh, Chang Beom Lee, Dong-Jun Kim, Hye Soon Kim, Ji Oh Mok, Tae Seo Sohn, Jeong Hyun Park, Sung Hee Choi, Sungrae Kim, Sang Soo Kim, Kyu Yeon Hur, Chong Hwa Kim, Young Min Cho, Byung-Joon Kim, Kun-Ho Yoon
Diabetes Obes Metab 27(10) 5727-5736
摘要
摘要
AIMS: To evaluate the efficacy and safety of adding lobeglitazone to a triple therapy regimen in Korean patients with type 2 diabetes whose blood glucose levels were inadequately controlled despite dual therapy with metformin and sitagliptin. MATERIALS AND METHODS: This randomised, double-blind, placebo-controlled, phase 3 study involved 231 Korean patients with type 2 diabetes whose HbA1c levels ranged from 7.0% to 10.0% despite treatment with metformin (≥1000 mg/day) and sitagliptin (100 mg/day). Participants received lobeglitazone (0.5 mg/day) or placebo for 24 weeks, followed by a 28-week open-label phase in which all patients received lobeglitazone. The primary endpoint was the change in glycated haemoglobin (HbA1c) at 24 weeks; secondary endpoints included changes in fasting plasma glucose (FPG), homeostatic model assessment for insulin resistance (HOMA-IR), HOMA for β-cell function (HOMA-β), quantitative insulin-sensitivity check index (QUICKI) and lipid profile. Safety assessments were also conducted. RESULTS: At week 24, lobeglitazone treatment demonstrated a significantly greater reduction in HbA1c compared with placebo (-1.00% ± 0.09% vs. 0.02% ± 0.09%), with a between-group difference in the adjusted mean change [-1.03%; p < 0.0001]. Additionally, lobeglitazone significantly reduced FPG compared with placebo at week 24 and improved HOMA-IR, HOMA-β and QUICKI. Lipid parameters were also improved by lobeglitazone administration. Adverse events were similar in both treatment arms. CONCLUSIONS: The addition of lobeglitazone in patients with type 2 diabetes inadequately controlled with metformin and sitagliptin is a beneficial therapeutic option, not only providing effective glycaemic control but also improving insulin function such as sensitivity and enhancing certain lipid parameters.
KM 提取结果
0 个 Figure · 0 个 KM 面板
其他 Figure(3,默认折叠)
这些图片未产生 KM 曲线结果,不在主页面重复展示。